BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Calendar//CN-US Event Research//ZH
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Calendar
X-WR-CALDESC:Market-moving event research, reminders and post-event review.
BEGIN:VEVENT
UID:evt-nvcr-trident-q2-2026-gbm-readout@catalyst-calendar.local
DTSTAMP:20260601T102452Z
DTSTART:20260601T130000Z
DTEND:20260601T133000Z
SUMMARY:Novocure TRIDENT三期新诊断GBM顶线数据读出窗口
DESCRIPTION:Novocure在一季报中确认TRIDENT三期试验新诊断胶质母细胞瘤顶线数据预计于2026年二季度读出。该试验验证TTFields是否可前移至放疗同步阶段，结果可能影响肿瘤电场治疗平台和GBM治疗路径预期。\\nImpact score: 74\\nExpected: 顶线数据将验证TTFields前移治疗策略，对NVCR及医疗器械肿瘤治疗平台预期有二元影响。\\nAffected: NVCR(subject\, unknown\, score 86)\; XBI(etf\, mixed\, score 55)\; MRK(peer\, mixed\, score 40)\\nSources: Novocure Q1 2026 results: https://investor.novocure.com/news-releases/news-release-details/novocure-reports-first-quarter-2026-financial-results\\nInformation only. Not investment advice.
URL:https://0.0.0.0:3000/?event=evt-nvcr-trident-q2-2026-gbm-readout
CATEGORIES:guidance\,US\,GBM\,Phase 3\,TTFields\,clinical readout
SEQUENCE:0
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:Review catalyst preview: Novocure TRIDENT三期新诊断GBM顶线数据读出窗口
END:VALARM
BEGIN:VALARM
TRIGGER:PT24H
ACTION:DISPLAY
DESCRIPTION:Complete post-event review: Novocure TRIDENT三期新诊断GBM顶线数据读出窗口
END:VALARM
END:VEVENT
END:VCALENDAR